latest news releases from the newsroom
LBO Capital Corp.
LBO Capital Completes Share Exchange
FARMINGTON HILLS, Mich., May 5, 2009 (GLOBE NEWSWIRE) -- LBO Capital Corp. (Other OTC:LBOA), a Colorado corporation (LBO Capital), announced completing acquisition of 100% of the common shares of subsidiaries Global Tech International, Inc. (Global Tech) and Advanced Digital Components, Inc. (Advanced Digital), Delaware corporations, by an exchange of stock with shareholders.
Propalms, Inc. Receives Orders From 46 U.S. Medical Facilities Through Healthcare Integrator
MALTON, England, May 5, 2009 (GLOBE NEWSWIRE) -- Propalms, Inc. (OTCBB:PRPM) is pleased to announce that the Company has received orders for its Terminal Services Edition (TSE) 6.0 software from medical facilities throughout the United States. Propalms received these orders through one of its American resellers, DocuTAP. DocuTAP sold over 600 licenses to these facilities.
NYFIX Schedules Annual Meeting of Stockholders
NEW YORK, May 5, 2009 (GLOBE NEWSWIRE) -- NYFIX (Nasdaq:NYFX), a trusted provider of innovative solutions that optimize trading efficiency, today announced that it will hold its 2009 Annual Meeting of Stockholders on Monday, June 15, 2009, beginning at 9:00 a.m., Eastern Daylight Time, at Bayard's, One Hanover Square, New York, NY 10004.
Changing Times Vitamins, Inc.
RecoveryX Named Official Drink of the Manny Pacquiao Training Camp
SCOTTSDALE, Ariz., May 5, 2009 (GLOBE NEWSWIRE) -- Changing Times Vitamins, Inc. (Pink Sheets:SGTB) announced today that their patent pending sports drink, RecoveryX, has been named the Official Sports Drink of the Manny Pacquiao Training Camp. RecoveryX was first introduced to Pacquiao prior to his successful fight with Oscar De la Hoya last year.
Immunomedics Announces U.S. Patent for Dock-And-Lock
MORRIS PLAINS, N.J., May 5, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that IBC Pharmaceuticals, Inc., a majority-owned subsidiary (IBC), has received notice that its patent application for "Multivalent immunoglobulin-based bioactive assemblies" will issue as U.S. patent no. 7,527,787 today.
Pain Therapeutics, Inc.
Pain Therapeutics Initiates Clinical Study in Cancer Patients
SAN MATEO, Calif., May 5, 2009 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), announced the initiation of another clinical study for PTI-188, an investigational drug intended to treat a lethal form of skin cancer called metastatic melanoma (MM). This study follows the release of promising data in an earlier Phase I study for PTI-188, published at the Meeting of the Society for Nuclear Medicine.